Can optimal primary cytoreduction be predicted in advanced stage epithelial ovarian cancer? Role of preoperative serum CA-125 level

Gynecol Obstet Invest. 2004;57(3):153-6. doi: 10.1159/000076236. Epub 2004 Jan 15.

Abstract

The aim of this study was to determine the ability of preoperative serum CA-125 levels to predict optimal cytoreduction in patients with stage III epithelial ovarian cancer. A retrospective review was made of the records of 40 patients with FIGO stage III ovarian carcinoma who underwent primary cytoreductive surgery. A receiver operating characteristic (ROC) curve was used to determine the most useful CA-125 level in predicting optimal versus suboptimal tumour cytoreduction. Twenty-two (55%) patients were optimally cytoreduced (residual disease <or=1 cm). A preoperative serum CA-125 level of 500 U/ml was found to be the value with the most predictive power. Optimal cytoreduction was obtained in 16 of the 21 cases (76%) with a CA-125 <500 U/ml compared to only 6 of the 19 cases (32%) with a CA-125 >500 U/ml. At this threshold, preoperative serum CA-125 level was able to predict optimal versus suboptimal cytoreduction with a sensitivity of 72%, specificity of 73%, positive predictive value of 68%, and negative predictive value of 76%. In the management of patients with advanced epithelial ovarian carcinoma, preoperative serum CA-125 level may help to predict optimal primary cytoreduction and to identify candidates for alternative approaches other than traditional primary cytoreductive surgery, such as neoadjuvant chemotherapy.

MeSH terms

  • Adenocarcinoma / blood
  • Adenocarcinoma / surgery
  • Adenocarcinoma, Clear Cell / blood
  • Adenocarcinoma, Clear Cell / surgery
  • Adenocarcinoma, Mucinous / blood
  • Adenocarcinoma, Mucinous / surgery
  • Adult
  • Aged
  • CA-125 Antigen / blood*
  • Carcinoma, Endometrioid / blood
  • Carcinoma, Endometrioid / surgery
  • Cystadenocarcinoma, Papillary / blood
  • Cystadenocarcinoma, Papillary / surgery
  • Female
  • Humans
  • Middle Aged
  • Neoplasm Staging
  • Ovarian Neoplasms / blood
  • Ovarian Neoplasms / surgery*
  • Preoperative Care
  • Retrospective Studies
  • Sensitivity and Specificity
  • Survival Rate
  • Treatment Outcome*

Substances

  • CA-125 Antigen